iRhythm Technologies, Inc. announced that Mintu Turakhia, M.D. M.A.S., will join the company in the new role of Chief Medical Officer and Chief Scientific Officer. Dr. Turakhia will join the executive leadership team to drive continued innovation, lead research and evidence generation, and enhance and augment the portfolio of clinical products and services. Dr. Turakhia is an internationally recognized cardiac electrophysiologist and leader in digital health and heart rhythm care.

He brings over 20 years of experience in patient care, outcomes research and trials, data science and artificial intelligence, medical device regulation, and the creation and commercialization of digital health products. In 2014, Dr. Turakhia performed the first-ever study of silent atrial fibrillation with the original Zio patch1, which helped to propel the field to perform large atrial fibrillation studies at scale, including the iRhythm mSToPS Clinical Trial2. Dr. Turakhia is also a seasoned operator who has led the development of virtual care and remote patient monitoring software for clinical trials, academic research, and commercialized health care products.

Additionally, iRhythm's Chief Clinical Officer Judy Lenane has announced her intention to retire from the company after nearly fourteen years of service. Ms. Lenane has been a highly valued member of the iRhythm leadership team since joining the company in 2008.